Survival advantage for carboplatin substituting cisplatin in combination with vindesine and mitomycin C for stage IIIB and IV squamous-cell bronchogenic carcinoma: a randomized phase III study

This publication has 19 references indexed in Scilit:

• Carboplatin versus cisplatin in solid tumors: An analysis of the literature
  Annals of Oncology, 1998
• A randomized trial of cisplatin, etoposide and bleomycin (PEB) versus carboplatin, etoposide and bleomycin (CEB) for patients with ‘good-risk’ metastatic non-seminomatious germ cell tumors
  Annals of Oncology, 1996
• Carboplatin and cisplatin: are they equivalent in efficacy in ?optimal residual? advanced ovarian cancer?
  Zeitschrift für Krebsforschung und Klinische Onkologie, 1996
• Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients: A randomized phase II study
  Cancer, 1996
• Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials
  BMJ, 1995
• Combination chemotherapy with mitomycin, vindesine, and cisplatin for non-small cell lung cancer association of antitumor activity with initial tumor burden and treatment center
  Cancer, 1990
• Carboplatin: current status and future prospects
  Cancer Treatment Reviews, 1988
• Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial.
  Journal of Clinical Oncology, 1988
• Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II
  Cancer Chemotherapy and Pharmacology, 1982
• Reporting results of cancer treatment
  Cancer, 1981